CD19 and diffuse large B-cell lymphoma: In 2020, the anti-CD19 Fc-modified antibody immunotherapy tafasitamab received accelerated approval for patients with relapsed or refractory (r/r) DLBCL, not eligible for autologous stem cell transplant, in combination with the immunomodulatory drug lenalidomide (1).